408,950 Shares in Drugs Made In America Acquisition II Corp. $DMII Acquired by Wealthspring Capital LLC

Wealthspring Capital LLC bought a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 408,950 shares of the company’s stock, valued at approximately $4,049,000.

Other hedge funds have also recently bought and sold shares of the company. Deltec Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $495,000. Wolverine Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $10,521,000. Finally, ABC Arbitrage SA acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $396,000.

Drugs Made In America Acquisition II Stock Performance

NASDAQ:DMII opened at $10.03 on Thursday. The company’s fifty day simple moving average is $9.99. Drugs Made In America Acquisition II Corp. has a twelve month low of $9.86 and a twelve month high of $10.03.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DMII. Weiss Ratings began coverage on shares of Drugs Made In America Acquisition II in a research report on Monday, March 2nd. They set a “sell (e)” rating on the stock. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.